Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

If Approved for Marketing in the United States, Trade Name Will be

Effient(TM)

TOKYO and INDIANAPOLIS, Jan. 4 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA). Prasugrel is an oral antiplatelet agent, initially in development for the treatment of patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI), including coronary stenting.

If approved for marketing in the United States, the trade name for prasugrel will be Effient(TM), company officials added.

"We are elated," said J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for prasugrel. "We feel confident in the strength and completion of this submission package, and plan to complete our submission in Europe in the first quarter of 2008. The benefit/risk profile of this compound, in comparison with the current standard of care, has the potential to improve outcomes for ACS patients undergoing PCI."

The NDA is based upon data from several trials, including the landmark TRITON-TIMI 38 clinical trial, which evaluated the safety and efficacy of prasugrel compared with clopidogrel (Plavix(R)/Iscover(R)) in reducing ischemic events such as non-fatal heart attack, non-fatal stroke and cardiovascular death in 13,608 patients. In the study, treatment with prasugrel resulted in a:
-- 19 percent relative risk reduction compared with clopidogrel in all ACS

patients in the primary composite endpoint of non-fatal heart atta
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Conn., April 29 Core Informatics announces,that it ... LIMS product,to BioRelix Pharmaceuticals of New Haven, CT. ... the need to establish a,strong data management infrastructure ... the LIMS marketplace, BioRelix choose the Core LIMS., ...
... Aflac and the American,Association for Cancer Research (AACR) ... Development Award for Childhood Cancer Research,endowed by Aflac ... cancer. The award,which includes a two-year grant of ... in San Diego, Calif., to Dr. Charles G. ...
... Points from the First Quarter of 2007 to ... 66.3% - Company Prepares to Launch ... ... leading developer and manufacturer of a broad array of,light-based aesthetic treatment systems, today announced record revenues,and ...
Cached Biology Technology:Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 2Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 2Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 4Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 5Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 6Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 7Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 8Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 9Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 10Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 11
(Date:4/16/2014)... Sometimes known as Kennedy,s disease, spinal and bulbar muscular atrophy ... progressive muscle weakness and atrophy. Researchers have long considered it ... the cells in the spinal cord and brainstem that control ... the April 16, 2014 online issue of Neuron , ...
(Date:4/16/2014)... store memories improves during childhood, associated with structural changes ... parietal cortices. New research from UC Davis is exploring ... Eventually, that could give insights into disorders that typically ... affect memory, such as schizophrenia and depression. , Located ...
(Date:4/15/2014)... Ohio (April 16, 2014)A new study from the Women,s ... D levels and menopause symptoms. The study was published ... The North American Menopause Society., The authors analyzed the ... a number of menopause symptoms, including hot flashes, night ...
Breaking Biology News(10 mins):Mutant protein in muscle linked to neuromuscular disorder 2How kids' brain structures grow as memory develops 2Low Vitamin D may not be a culprit in menopause symptoms 2
... April 9, 2012 Scientists from Duke University Medical ... switches can define clinically relevant molecular subtypes of ovarian ... prognostic and diagnostic testing. These bimodal genes can define ... to different therapeutic regimens. The researchers, results are ...
... to predictions of which plant species will escape extinction from ... world, posing a great challenge to plants in all ecosystems, ... biology and senior author of the research. Scientists have debated ... are most vulnerable. Sack and two members ...
... (Boston) Researchers at Boston University School of Medicine ... population of pure lung and thyroid progenitor cells in ... and thyroid tissue formation. The research, which will be ... Cell Stem Cell , identifies factors necessary for ...
Cached Biology News:Researchers identify genes that may help in ovarian cancer diagnosis and prognosis 2Which plants will survive droughts, climate change? 2Which plants will survive droughts, climate change? 3Which plants will survive droughts, climate change? 4Which plants will survive droughts, climate change? 5BU researchers derive purified lung and thyroid progenitors from embryonic stem cells 2
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... The E. coli protein sample is ... give a consistent pattern when used ... and sample buffer. This sample can ... validate your 2-D system and protocol ...
Biology Products: